Contact
searchSearch
HMP Global

PharmLaw

PharmLaw
Former Done Global CEO, Clinical President Sentenced in Telehealth Adderall Fraud Case
07/08/2026
Grace Taylor, MS, MA
Former executives of Done Global were sentenced to federal prison after convictions in a multimillion-dollar scheme involving unlawful telehealth prescribing of Adderall and health care fraud, according to the US Department of Justice.
Former executives of Done Global were sentenced to federal prison after convictions in a multimillion-dollar scheme involving unlawful telehealth prescribing of Adderall and health care fraud, according to the US Department of Justice.
Former executives of Done Global...
07/08/2026
Pharmacy Learning Network
PharmLaw
DOJ Telemedicine Fraud Case Underscores Compliance Risks for Health Care Organizations
07/01/2026
Hannah Musick
A US Department of Justice (DOJ) enforcement action against a telemedicine company owner underscores continuing regulatory scrutiny of telemedicine prescribing, kickback arrangements, and Medicare billing practices.
A US Department of Justice (DOJ) enforcement action against a telemedicine company owner underscores continuing regulatory scrutiny of telemedicine prescribing, kickback arrangements, and Medicare billing practices.
A US Department of Justice (DOJ)...
07/01/2026
Pharmacy Learning Network
PharmLaw
PBM Trade Group Challenges Illinois Drug Pricing Transparency Law on ERISA Grounds
06/24/2026
Hannah Musick
The Pharmaceutical Care Management Association has sued Illinois to block key provisions of the state's Prescription Drug Affordability Act, setting up a legal challenge that could shape the future of pharmacy benefit manager (PBM)...
The Pharmaceutical Care Management Association has sued Illinois to block key provisions of the state's Prescription Drug Affordability Act, setting up a legal challenge that could shape the future of pharmacy benefit manager (PBM)...
The Pharmaceutical Care...
06/24/2026
Pharmacy Learning Network
PharmLaw
Ahold Delhaize USA to Pay $40 Million in Drug Price Claims Settlement
06/16/2026
Grace Taylor, MS, MA
Ahold Delhaize USA agreed to pay $40 million to resolve allegations that supermarket pharmacies reported inflated usual and customary drug prices to federal health care programs.
Ahold Delhaize USA agreed to pay $40 million to resolve allegations that supermarket pharmacies reported inflated usual and customary drug prices to federal health care programs.
Ahold Delhaize USA agreed to pay...
06/16/2026
Pharmacy Learning Network
PharmLaw
Tennessee Nurse Practitioner Found Guilty in Controlled-Substance Prescribing Case
06/02/2026
Grace Taylor, MS, MA
A Tennessee nurse practitioner has been convicted of illegally distributing Schedule II opioids, according to the Department of Justice.
A Tennessee nurse practitioner has been convicted of illegally distributing Schedule II opioids, according to the Department of Justice.
A Tennessee nurse practitioner...
06/02/2026
Pharmacy Learning Network
PharmLaw
CVS Challenges Tennessee Law Restricting PBM Ownership of Pharmacies
05/27/2026
Hannah Musick
CVS Health has sued the Tennessee state legislature over a new law barring pharmacy benefit managers (PBMs) from owning pharmacies, setting up a potentially significant legal battle over state authority to regulate vertically integrated...
CVS Health has sued the Tennessee state legislature over a new law barring pharmacy benefit managers (PBMs) from owning pharmacies, setting up a potentially significant legal battle over state authority to regulate vertically integrated...
CVS Health has sued the...
05/27/2026
Pharmacy Learning Network
PharmLaw
North Carolina Reaches $11 Million EpiPen Settlement Over Pricing Practices
05/06/2026
Grace Taylor, MS, MA
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11 million settlement with Mylan over alleged EpiPen pricing and rebate practices that impacted Medicaid and state health plan costs.
North Carolina secured an $11...
05/06/2026
Pharmacy Learning Network
PharmLaw
Purdue Pharma Sentenced in Federal Opioid Case, Finalizing Fraud and Kickback Conspiracy Resolution
04/29/2026
Grace Taylor, MS, MA
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal sentencing finalizes a landmark opioid case involving fraud and kickback conspiracies, with lasting compliance implications for the pharmaceutical supply chain.
Purdue Pharma’s federal...
04/29/2026
Pharmacy Learning Network
PharmLaw
Drug Lobby Challenges Washington State 340B Pharmacy Law
04/27/2026
Grace Taylor, MS, MA
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade group has filed a federal lawsuit challenging Washington state’s new 340B law, arguing it unlawfully interferes with manufacturer control over drug distribution and pricing requirements.
A leading pharmaceutical trade...
04/27/2026
Pharmacy Learning Network
PharmLaw
Executive Order Targets Accelerated Development and Access Pathways for Psychedelic Therapies in Mental Health
04/21/2026
Hannah Musick
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs federal agencies to accelerate the development, review, and potential patient access to investigational psychedelic therapies for serious mental illness, signaling a shift in regulatory and research priorities...
A new executive order directs...
04/21/2026
Pharmacy Learning Network
Breaking News
News
Expert Perspectives
Commentary

FDA Drug Recalls

News
ADHD Medication Recalled Due to Incorrect Labeling
07/09/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for combination extended-release capsules of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate due to a...
The US Food and Drug Administration (FDA) has issued a Class II recall for combination extended-release capsules of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate due to a...
The US Food and Drug...
07/09/2026
Pharmacy Learning Network
News
Synjardy XR Tablets Recalled Due to CGMP Deviations
07/09/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Synjardy XR (empagliflozin and metformin hydrochloride) tablets due to Current Good Manufacturing Practice (CGMP) deviations, affecting 560 bottles.
The US Food and Drug Administration (FDA) has issued a Class II recall for Synjardy XR (empagliflozin and metformin hydrochloride) tablets due to Current Good Manufacturing Practice (CGMP) deviations, affecting 560 bottles.
The US Food and Drug...
07/09/2026
Pharmacy Learning Network
News
Imuldosa Injections Recalled Due to Lack of Sterility Assurance
07/09/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for Imuldosa (ustekinumab-srlf) injections due to a lack of sterility assurance, affecting 326 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for Imuldosa (ustekinumab-srlf) injections due to a lack of sterility assurance, affecting 326 vials.
The US Food and Drug...
07/09/2026
Pharmacy Learning Network
News
Lacosamide Tablets Recalled Due to the Presence of Foreign Tablets
07/02/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for lacosamide tablets, 100 mg, due to the presence of foreign tablets, affecting 31 392 bottles.
The US Food and Drug Administration (FDA) has issued a Class II recall for lacosamide tablets, 100 mg, due to the presence of foreign tablets, affecting 31 392 bottles.
The US Food and Drug...
07/02/2026
Pharmacy Learning Network
News
Cinacalcet Tablets Recalled Due to CGMP Deviations
07/02/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for sensipar (cinacalcet) tablets due to Current Good Manufacturing Practice (CGMP) deviations, affecting 9565 bottles.
The US Food and Drug Administration (FDA) has issued a Class II recall for sensipar (cinacalcet) tablets due to Current Good Manufacturing Practice (CGMP) deviations, affecting 9565 bottles.
The US Food and Drug...
07/02/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use